Sergey Brin's Bayshore Global absorbs Nexus NeuroTech Ventures — $200M brain-health VC folds into family office
Summary
Sergey Brin's family office Bayshore Global Management absorbed Nexus NeuroTech Ventures — a $200M brain-health VC fund managing approximately 15 companies across neurodegenerative, neuropsychiatric, and neurodevelopmental areas — which closed operations on March 31, 2026. CEO Jordi Parramon confirmed the closure on LinkedIn, noting portfolio companies had helped over 200,000 individuals and generated more than 50 ongoing clinical studies. Brin's nonprofit Catalyst4 held approximately 95% stake across Nexus vehicles, making the absorption a consolidation of capital already under Brin's effective control. Through Catalyst4, Brin has invested over $600M into neurotech startups and funds — approximately $400M in 2024 alone — including $1.75B total on Parkinson's research.
Why it matters
Brin absorbing Nexus into Bayshore brings $200M of neurotech investment under direct family office control, enabling longer time horizons and fewer structural constraints than a traditional VC fund. The move signals that ultra-wealthy individuals are building permanent, in-house neurotech investment platforms — a trend also visible in Jeff Bezos (Synchron) and Bill Gates (Synchron, Alzheimer's). The 15 Nexus portfolio companies retain backing but now report to Bayshore directly.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial